3882. Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk.
作者: Anna Felis-Giemza.;Mateusz Moskal.;Krzysztof Proc.;Zbigniew Guzera.;Marcin Stajszczyk.;Karolina Palej.;Kornelia Chmurzyńska.;Piotr Wiland.;Krzysztof Batko.;Bogdan Batko.
来源: Reumatologia. 2023年61卷6期414-423页
This multicenter, real-world, retrospective cohort study aimed to assess the effectiveness and safety of tofacitinib (TOFA) in rheumatoid arthritis (RA).
3883. Scleroderma-overlap syndromes: capillaroscopy, laboratory, and clinical manifestations and follow-up compared to scleroderma patients.
作者: Saeedeh Shenavandeh.;Zahra Azariyon.;Mohammad Ali Nazarinia.
来源: Reumatologia. 2023年61卷6期448-459页
Overlap syndrome (OS) is a group of systemic connective tissue diseases (CTDs) that meet the criteria of two or more CTDs. In this study, we evaluated clinical, laboratory, and capillaroscopic manifestations of patients with scleroderma OS (SSc-OS) and its subgroups and follow-up progression compared to patients with limited SSc (LcSSc).
3884. Newly developed cardiovascular risk factors in rheumatoid arthritis patients initiating biologic treatment.
作者: Wojciech Zaręba.;Piotr Krawiec.;Małgorzata Banaszkiewicz.;Krzysztof Batko.;Aleksandra Gołąb.;Dariusz Plicner.;Zbigniew Żuber.;Bogdan Batko.
来源: Reumatologia. 2023年61卷6期424-431页
Rheumatoid arthritis (RA) is a risk factor (RF) for cardiovascular (CV) disease, a leading cause of mortality in RA patients.
3885. Genetics of SLE: does this explain susceptibility and severity across racial groups?
作者: Karin Demkova.;David L Morris.;Timothy J Vyse.
来源: Rheumatology (Oxford). 2023年62卷Suppl 1期i15-i21页
The prevalence and severity of SLE have been found to vary across populations of different ancestries. This review explores whether these differences can be explained by the genetic aetiology of the condition. Large genetic studies suggest that populations of different ancestry share the same risk loci but individual risk alleles are more common in some, leading to a higher prevalence and severity and an earlier onset of the condition. Despite many of the loci being shared across populations, some have been found to be ancestry specific and these are hypothesized to have undergone differential selective pressure in recent human history. Additionally, the effectiveness of some of the drugs used in SLE has been found to vary across ancestries, which might affect progression of the disease, but it is unclear whether these differences are pharmacogenetic. We concluded that to understand the full role of genetics in the risk, presentation and response to treatment of SLE, larger studies including individuals from a wider representation of ancestries will be required.
3886. Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children: a multicentre retrospective study.
作者: Kfir Kaidar.;Yotam Dizitzer.;Philip J Hashkes.;Linda Wagner-Weiner.;Melissa Tesher.;Yonatan Butbul Aviel.;Kanteman Inbar.;Yackov Berkun.;Eli M Eisenstein.;Mohamad Hamad Saied.;Ofra Goldzweig.;Merav Heshin-Bekenstein.;Eduard Ling.;Michal Feldon.;Yoel Levinsky.;Rotem Tal.;Liora Harel.;Gil Amarilyo.
来源: Rheumatology (Oxford). 2023年62卷8期2829-2837页
To identify predictors of a severe clinical course of multisystem inflammatory syndrome in children (MIS-C), as defined by the need for inotropic support.
3887. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.
作者: Loïc Meudec.;Pauline Richebé.;Juliette Pascaud.;Xavier Mariette.;Gaetane Nocturne.
来源: Rheumatology (Oxford). 2023年62卷8期2855-2863页
Janus kinase inhibitors (JAKi) are efficacious in RA but concerns regarding the risk of cancer associated with their exposure have recently emerged. Given the role of NK cells in antitumour response, we investigated the impact of JAKi [tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA) and filgotinib (FIL)] on NK cells.
3888. Artificial intelligence in osteoarthritis: repair by knee joint distraction shows association of pain, radiographic and immunological outcomes.
作者: Mylène P Jansen.;Christoph Salzlechner.;Eleanor Barnes.;Matthew D DiFranco.;Roel J H Custers.;Fiona E Watt.;Tonia L Vincent.;Simon C Mastbergen.
来源: Rheumatology (Oxford). 2023年62卷8期2789-2796页
Knee joint distraction (KJD) has been associated with clinical and structural improvement and SF marker changes. The current objective was to analyse radiographic changes after KJD using an automatic artificial intelligence-based measurement method and relate these to clinical outcome and SF markers.
3889. A systemic sclerosis disease model: can inducible pluripotent stem cells fill an unmet need in defining vascular leak?
作者: Tracy M Frech.;Colin Maguire.;Aaron C Petrey.;Gregory J Stoddard.;Anthony J Donato.
来源: Rheumatology (Oxford). 2023年62卷7期e226-e228页 3890. Diagnostic and therapeutic algorithms for monogenic autoinflammatory diseases presenting with recurrent fevers among adults.
作者: Marion Delplanque.;Antoine Fayand.;Guilaine Boursier.;Gilles Grateau.;Léa Savey.;Sophie Georgin-Lavialle.
来源: Rheumatology (Oxford). 2023年62卷8期2665-2672页
Autoinflammatory diseases (AIDs) are defined as disorders of innate immunity. They were initially defined in contrast to autoimmune diseases because of the lack of involvement of the adaptive immune system and circulating autoantibodies. The four monogenic AIDs first described are called the 'historical' AIDs and include FMF (associated with MEFV mutations), cryopyrinopathies (associated with NLRP3 mutations), TNF receptor-associated periodic syndrome (associated with TNFRSF1A mutations) and mevalonate kinase deficiency (MKD; associated with MVK mutations). In the last 10 years, >50 new monogenic AIDs have been discovered due to genetic advances. The most important discovery for adult patients is VEXAS syndrome associated with somatic UBA1 mutations leading to an AID affecting mostly elderly men. Diagnosis of monogenic AIDs is based on personal and family history and detailed analysis of symptoms associated with febrile attacks in the context of elevated peripheral inflammatory markers. This review proposes a practical approach for the diagnosis of the main monogenic AIDs among adult patients.
3891. Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis.
作者: Fanni A Meznerics.;Lajos V Kemény.;Emese Gunther.;Eszter Bakó.;Fanni Dembrovszky.;Bence Szabó.;Anna Ascsillán.;Elmar Lutz.;Dezsö Csupor.;Péter Hegyi.;András Bánvölgyi.;György Nagy.
来源: Rheumatology (Oxford). 2023年62卷6期2048-2059页
The multibiomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in RA. Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.
3892. Evaluation of the agreement between the ACR 1990 fibromyalgia tender points and an enthesitis score in patients with axial spondyloarthritis.
作者: Faten Hamitouche.;Clementina Lopez-Medina.;Laure Gossec.;Serge Perrot.;Maxime Dougados.;Anna Moltó.
来源: Rheumatology (Oxford). 2023年62卷8期2757-2764页
Coexistence of FM represents a challenge in the evaluation of enthesitis in patients with axial spondyloarthritis (axSpA) due to a possible overlap between the tender points (TP) due to enthesitis and those of FM. The objective was to assess the agreement between the MASES enthesitis score and the tender points of the ACR 1990 criteria in patients with axSpA.
3893. Ultrasound-guided core needle biopsy and incisional biopsy of the parotid gland are comparable in diagnosis of primary Sjögren's syndrome.
作者: Liselotte Deroo.;Eva Genbrugge.;Frederick Dochy.;David Creytens.;Helena Achten.;Kristel De Boeck.;Wouter Bauters.;Dimitri Roels.;Joke Deprez.;Filip Van den Bosch.;Dirk Elewaut.;Isabelle Peene.
来源: Rheumatology (Oxford). 2023年62卷8期2765-2772页
Salivary gland lymphocytic infiltrates are a hallmark of primary SS (pSS), but traditional biopsy techniques hold several disadvantages. Ultrasound-guided core needle (US-guided CN) parotid gland biopsy is minimally invasive and reliable for diagnosis of lymphoma in pSS. This proof-of-concept study aimed to explore this technique in the diagnostic work-up of pSS and is the first to address its value in a consecutive cohort independently of the presence of salivary gland swelling.
3894. Evaluation of asymptomatic cerebral ischemia by arterial spin-labeling magnetic resonance imaging of the brain in Takayasu arteritis.
作者: Katsuhide Kusaka.;Shingo Nakayamada.;Shigeru Iwata.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2023年62卷7期e235-e236页 3895. Busting the myth of methotrexate chronic hepatotoxicity.
作者: Vincent Di Martino.;Delphine Weil Verhoeven.;Frank Verhoeven.;François Aubin.;Jérome Avouac.;Lucine Vuitton.;Frédéric Lioté.;Thierry Thévenot.;Daniel Wendling.
来源: Nat Rev Rheumatol. 2023年19卷2期96-110页
Methotrexate is a key component of the treatment of inflammatory rheumatic diseases and the mainstay of therapy in rheumatoid arthritis. Hepatotoxicity has long been a concern for prescribers envisaging long-term treatment with methotrexate for their patients. However, the putative liver toxicity of methotrexate should be evaluated in the context of advances in our knowledge of the pathogenesis and natural history of liver disease, especially non-alcoholic fatty liver disease (NAFLD). Notably, patients with NAFLD are at increased risk for methotrexate hepatotoxicity, and methotrexate can worsen the course of NAFLD. Understanding the mechanisms of acute hepatotoxicity can facilitate the interpretation of elevated concentrations of liver enzymes in this context. Liver fibrosis and the mechanisms of fibrogenesis also need to be considered in relation to chronic exposure to methotrexate. A number of non-invasive tests for liver fibrosis are available for use in patients with rheumatic disease, in addition to liver biopsy, which can be appropriate for particular individuals. On the basis of the available evidence, practical suggestions for pretreatment screening and long-term monitoring of methotrexate therapy can be made for patients who have (or are at risk for) chronic liver disease.
3896. Immune complex-mediated neutrophil activation in patients with polymyalgia rheumatica.
作者: Despina Michailidou.;Linda Johansson.;Runa Kuley.;Ting Wang.;Payton Hermanson.;Solbritt Rantapää-Dahlqvist.;Christian Lood.
来源: Rheumatology (Oxford). 2023年62卷8期2880-2886页
Neutrophils are important in host defence. However, neutrophils are also linked to inflammation and organ damage. The purpose of this study was to assess whether markers of neutrophil activation are increased in PMR.
3897. Incidence of septic arthritis in patients with ankylosing spondylitis and seropositive rheumatoid arthritis following TNF inhibitor therapy.
作者: Hyung Woo Kim.;Minkyung Han.;Inkyung Jung.;Sung Soo Ahn.
来源: Rheumatology (Oxford). 2023年62卷8期2740-2747页
Septic arthritis (SA) is a serious complication occurring in the joints, and its risk increases with immunosuppressive therapy. This study investigated whether TNF inhibitors increase the risk of SA in patients with AS and seropositive RA (SPRA).
3898. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
作者: Manuel Alfredo Podestà.;Federica Mescia.;Anna Ricchiuto.;Rona Smith.;Martina Tedesco.;Matthias Arnaldo Cassia.;Julia Holle.;Renato Alberto Sinico.;Annette Bruchfeld.;Iva Gunnarsson.;Sophie Ohlsson.;Bo Baslund.;Zdenka Hruskova.;Vladimir Tesar.;Gianmarco Sabiu.;Maurizio Gallieni.;Maria C Cid.;Augusto Vaglio.;Lorraine Harper.;Mario Cozzolino.;Francesco Scolari.;David Jayne.;Federico Alberici.
来源: Rheumatology (Oxford). 2023年62卷8期2850-2854页
Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculitis (AAV). B-cell depletion may increase the risk of hypogammaglobulinemia, potentially leading to severe infections. This study aims to assess factors associated with hypogammaglobulinemia in AAV patients treated with rituximab.
3899. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply.
作者: Alexander N R Weber.;Ana Tapia-Abellán.;Xiao Liu.;Juan I Aróstegui.;Pablo Pelegrín.;Tatjana Welzel.;Jasmin B Kuemmerle-Deschner.
来源: Rheumatology (Oxford). 2023年62卷5期e168-e169页 |